chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: Pneumococcal infection; Information has been download from Regulatory Agency on 12-JAN-2024.  This spontaneous report was referring to an adult female patient (55-59 years old). The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided). The patient received pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) for 1 time in total.  On an unknown date in 2010, the patient experienced pneumococcal infection, the streptococcus pneumoniae serotyping was not available. At the time of reporting, the outcome of the event pneumococcal infection was unknown.   The causal relationship between pneumococcal infection and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event pneumococcal infection was determined to be medically significant.
Age: 95.0
Sex: F
Vaccine: COVID19
Symptoms: Neoplasm, Swelling face
Clinical narrative: Bulbous fluid filled tumor on point of elbow and puffy face
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from Health Authority on 12-JAN-2024.  This spontaneous report was referring to a female adult patient (age: 25-29). The patient's medical history, historical drugs, concurrent conditions, and concomitant drugs were not reported  On an unknown date, the patient was vaccinated with the first dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.  On an unknown date in 2012, the patient experienced Streptococcus pneumoniae pneumonia. On an unknown date in 2012, Streptococcus pneumoniae serotyping was not available. At the time of reporting, the outcome of the event Streptococcus pneumoniae pneumonia was not known.  The causal relationship between the event and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) was not provided.  Upon internal review, the event of streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from Regulatory Authority via Case Line Listing on 12-JAN-2024 concerning an adult female patient (reported as 60-64 years old). The patient's concurrent condition, medical history and concomitant medication were not provided.  On unknown dates, the patient was vaccinated with 3 doses of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.   On an unknown date in 2016, the patient experienced pneumonia, streptococcus pneumoniae serotyping showed not available. The outcome of the event was unknown.  The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of pneumonia pneumococcal was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal bacteraemia
Clinical narrative: Bacteraemia; Information has been received from Regulatory Agency 12-JAN-2024.  This spontaneous report has been downloaded from Surveillance System and referring to a male patient (age: from 35-39 years old). The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated 1 time of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2016, the patient experienced pneumococcal bacteraemia. On an unknown date in 2016, streptococcus pneumoniae serotyping result was not available. At the time of reporting, the outcome of the event pneumococcal bacteraemia was not known.   The causal relationship between pneumococcal bacteraemia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event of pneumococcal bacteraemia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal bacteraemia, Streptococcus test positive
Clinical narrative: Pneumococcal bacteraemia;   This spontaneous report was referring to an elderly male patient (age: 75-79). The patient's medical history, concurrent conditions, and concomitant drugs were not reported.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.   On an unknown date in 2009, the patient experienced pneumococcal bacteraemia. On an unknown date in 2009, streptococcus pneumoniae serotyping showed not available. At the time of reporting, the outcome of the event pneumococcal bacteraemia was unknown. The action taken with suspect vaccine was not applicable.  The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of pneumococcal bacteraemia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal, Streptococcus test positive
Clinical narrative: Streptococcus pneumoniae pneumonia; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report as received from a Health Authority refers to a male elderly patient of unknown exact age (age group reported as '85+'). No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided.  On unknown day, the patient was vaccinated with a first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX 23) (dose, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis.   On an unknown date in 2012, the patient experienced pneumococcal pneumonia. Streptococcus pneumoniae serotyping was not available. The outcome of the event was not reported.        The relatedness between pneumococcal pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX 23) was not provided.  Upon internal review, the event of pneumococcal pneumonia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: pneumonia; Information has been received from Health Authority (Agency number not provided) on 12-JAN-2024.   This spontaneous report was received from National Notifiable Diseases Surveillance System (NNDSS) and refers to a 60-64-year-old female patient (exact age was not provided). Information regarding the patient's concurrent conditions, medical history, and concomitant medications was not provided.   On an unknown date, the patient was vaccinated with first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) (exact dose, frequency, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis.  On an unknown date in 2012, the patient experienced Streptococcus pneumoniae pneumonia, and Streptococcus pneumoniae serotyping result was reported as not available. The outcome of the event was not reported.   The relatedness between the event and the suspect vaccine was not provided.   Upon internal review, the event of Streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumococcal bacteraemia, Streptococcus test positive
Clinical narrative: Bacteraemia; Information has been received from Agency on 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Authority and referring to an adult female patient (age: 45-49 years old). The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On unknown dates, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, 1 time, for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2009, the patient experienced bacteremia (pneumococcal bacteraemia). On an unknown date in 2009, streptococcus pneumoniae serotyping showed not applicable. At the time of reporting, the outcome of the event pneumococcal bacteraemia was not known.  The causal relationship between pneumococcal bacteraemia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event of pneumococcal bacteraemia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Meningitis pneumococcal
Clinical narrative: Streptococcus pneumoniae meningitis; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report as received from a Health Authority refers to a elderly female patient of unknown exact age (age group reported as "80-84"). No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided.     On an unknown date, the patient was vaccinated with a first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) (dose, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis. On an unknown date in 2013, the patient experienced streptococcus pneumoniae meningitis. Streptococcus pneumoniae meningitis serotyping was not available. The outcome of the event was not reported.  The relatedness between streptococcus pneumoniae meningitis and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of streptococcus pneumoniae meningitis was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal, Streptococcus test
Clinical narrative: Streptococcus pneumoniae pneumonia; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report as received from a National Notifiable Diseases Surveillance System (NNDSS) refers to a elderly male patient of unknown exact age (age group reported as "85+"). No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided.     On unknown dates, the patient was vaccinated with a first and second dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) (dose, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis. On an unknown date in 2013, the patient experienced streptococcus pneumoniae pneumonia. Streptococcus pneumoniae serotyping was not available. The outcome of the event was not reported.  The relatedness between streptococcus pneumoniae pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of streptococcus pneumoniae pneumonia was determined to be medically significant
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: Pneumococcal infection; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report as received from a Health Authority refers to a elderly male patient of unknown exact age (age group reported as "85+"). No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided.     On an unknown date, the patient was vaccinated with a first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (dose, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis. On an unknown date in 2013, the patient experienced pneumococcal infection (reported as "other"). Pneumococcal infection serotyping was not available. The outcome of the event was not reported.  The relatedness between pneumococcal infection and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of pneumococcal infection was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal bacteraemia
Clinical narrative: Pneumococcal bacteraemia;  This spontanous report was received from regulatory authority and refers to male patient over 85-years-old.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with two doses of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2013, the patient experienced Pneumococcal bacteraemia. On an unknown date in 2013, Streptococcus pneumoniae serotyping showed not available. At the time of reporting, the outcome of the event Pneumococcal bacteraemia was not known.   The causal relationship between Pneumococcal bacteraemia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown. Upon internal review the event of Pneumococcal bacteraemia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Streptococcus pneumoniae pneumonia; Information has been received from {HA} (agency number was not provided) on 12-JAN-2024 and refers to male patient of unknown exact age (age group reported as: 60-64, adult). The patient's medical history, concurrent conditions and concomitant therapies were not provided.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23), formulation: injection (lot #, expiration date, exact dose, route of administration and anatomical location were not reported) for prophylaxis. On an unknown date, the patient was vaccinated with the second dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23), formulation: injection (lot #, expiration date, exact dose, route of administration and anatomical location were not reported) for prophylaxis.  On unknown date in 2012, the patient experienced pneumonia pneumococcal. The Streptococcus pneumoniae serotyping was performed but the result was not available. The outcome of pneumonia pneumococcal was unknown.  The relatedness between the event of pneumonia pneumococcal and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.   The event of pneumonia pneumococcal was considered to be medically significant.
Sex: M
Vaccine: PNC, PPV
Symptoms: Pneumococcal bacteraemia, Streptococcus test
Clinical narrative: Pneumococcal bacteraemia; Information has been downloaded from regulatory authority on 12-JAN-2024.  This spontaneous report was received from regulatory authority and refers to a male child patient (age: 5-9). The patient's medical history, historical drugs, concurrent conditions, and concomitant drugs were not reported.  On unknown dates, the patient was vaccinated with a dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) injection for prophylaxis (strength, dose, route of administration, lot#, and expiration date were not reported) and three doses of pneumococcal vaccine conjugated 7-valent (PREVENAR) (strength, dose, route of administration, indication, lot#, and expiration date were not reported.  On an unknown date in 2013, the patient experienced pneumococcal bacteraemia (Streptococcus pneumoniae serotyping was not available). The outcome of the event was not reported. The causal relationship between the event and suspect vaccine was not provided.  Upon internal review, the event of pneumococcal bacteraemia was determined to be medically significant.
Sex: F
Vaccine: PNC, PPV
Symptoms: Pneumonia pneumococcal, Streptococcus test
Clinical narrative: Pneumonia; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report as received from a Regulatory Authority refers to an adolescent female patient of unknown exact age (age group reported as "10-14"). No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided.    On unknown date, the patient was vaccinated with first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) (dose, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis. On unknown dates, the patient was also vaccinated with three doses of pneumococcal vaccine conj 7V (CRM197) (PREVENAR) (dose, indication, route of administration, anatomical location, lot number and expiration date were not reported). On an unknown date in 2013, the patient experienced streptococcus pneumoniae pneumonia (reported as pneumonia). Streptococcus pneumoniae serotyping result was not available. The outcome of the event was not reported.  The relatedness between streptococcus pneumoniae pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from HA on 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Authority and refers to a male patient (70-74 years old). His medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (anatomical location, strength, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2012, the patient experienced pneumonia (Pneumonia pneumococcal). Streptococcus pneumoniae serotyping was not available. At the time of reporting, the outcome of the event was not known.  The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.  Upon internal review, the event of pneumonia (Pneumonia pneumococcal) was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from Health Authority on 12-JAN-2024.   This spontaneous report was received from National Notifiable Diseases Surveillance System (NNDSS) and refers to a 55-59-year-old female patient (exact age was not provided). Information regarding the patient's concurrent conditions, medical history, and concomitant medications was not provided.   On unspecified day, the patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) (exact dose, frequency, route of administration, anatomical location, lot number and expiration date were not reported) for prophylaxis.  On an unknown date in 2013, the patient experienced Streptococcus pneumoniae pneumonia, and Streptococcus pneumoniae serotyping result was reported as not available. The outcome of the event was not reported.   The relatedness between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.   Upon internal review, the event of Streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Meningitis pneumococcal
Clinical narrative: Meningitis; Information has been received from a Health Authority on 12-JAN-2024.  This spontaneous report was received from a National Notifiable Diseases Surveillance System (NNDSS) and refers to an adult female patient of unknown exact age (age group reported as 45-49 years old). No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided.  On an unknown dates, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, 3 times in total, administered for prophylaxis (strength, dose, anatomical location, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2013, the patient experienced Streptococcus pneumoniae meningitis. Information regarding serotype was reported as not available. The outcome of the event was not reported.   The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.  Upon internal review, the event of Streptococcus pneumoniae meningitis was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia
Clinical narrative: Pneumonia; Information has been received from Health Authority on 12-JAN-2024.  This spontaneous report has been downloaded from Surveillance System (SS) and refers to an adult (between 60 and 64 years old; reported as age group 60-64) male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown dates, the patient was vaccinated with 2 doses of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (exact dose, strength, lot #, expiry date, and route of administration were not provided). It was reported that the patient received total of 2 vaccinations.  In 2015, the patient experienced pneumonia, serotype: not available. The outcome of the event was not provided.   The causal relationship between pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.  Upon internal review, the event of pneumonia has been determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Bacteraemia
Clinical narrative: Bacteraemia; Information has been received from Health Authority on 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Authority and refers to an elderly (between 70 and 74 years old; reported as age group 70-74) male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (exact dose, strength, lot #, expiry date, and route of administration were not provided). It was reported that the patient received total of 1 vaccination.  In 2015, the patient experienced bacteraemia, serotype: not available. The outcome of the event was not provided.   The causal relationship between bacteraemia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.  Upon internal review, the event of bacteraemia has been determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from Health Authority (Agency number not provided), on 12-JAN-2024.   This spontaneous report has been received from Regulatory Authority, regarding an elder female patient (also reported as in her late seventies).   The patient's pertinent concurrent conditions, medical history, past drug reactions or allergies, and concomitant therapies were not provided.   On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23), injection (strength, exact dose, route and site of administration, lot number, and expiration date were not provided), for prophylaxis.   On an unknown date in 2017, streptococcus pneumoniae serotyping was not applicable. In this same date, streptococcus pneumoniae pneumonia developed (pneumonia pneumococcal).   At the time of reporting, the outcome of the event and the causality assessment between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) were not reported.    Upon internal review, the event streptococcus pneumoniae pneumonia was considered as medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumococcal bacteraemia
Clinical narrative: Pneumococcal bacteraemia; Information has been received from Health Authority (Agency number not provided), on 12-JAN-2024.   This spontaneous report has been received from Regulatory Authority, regarding an elder female patient (also reported as in her late seventies).   The patient's pertinent concurrent conditions, medical history, past drug reactions or allergies, and concomitant therapies were not provided.   On an unknown date, the patient was vaccinated with the second dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23), injection (strength, exact dose, route and site of administration, lot number, and expiration date were not provided), for prophylaxis.   On an unknown date in 2017, streptococcus pneumoniae serotyping was not available. In this same date, Pneumococcal bacteraemia developed.   At the time of reporting, the outcome of the event and the causality assessment between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) were not reported.    Upon internal review, the event Pneumococcal bacteraemia was considered as medically significant.
Sex: M
Vaccine: PPV
Symptoms: Meningitis pneumococcal, Pneumonia pneumococcal
Clinical narrative: Streptococcus pneumoniae meningitis; Streptococcus pneumoniae pneumonia; Information has been received from Health Authority (Agency number not provided), on 12-JAN-2024.   This spontaneous report has been received from Surveillance System, regarding an adult male patient (also reported as in her early fifties).   The patient's pertinent concurrent conditions, medical history, past drug reactions or allergies, and concomitant therapies were not provided.   On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23), injection (strength, exact dose, route and site of administration, lot number, and expiration date were not provided), for prophylaxis.   On an unknown date in 2017, streptococcus pneumoniae serotyping was not available. In this same date, Streptococcus pneumoniae meningitis (Meningitis pneumococcal) and Streptococcus pneumoniae pneumonia (Pneumonia pneumococcal) developed.   At the time of reporting, the outcome of the event and the causality assessment between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) were not reported.    Upon internal review, the event Streptococcus pneumoniae meningitis (Meningitis pneumococcal) and Streptococcus pneumoniae pneumonia (Pneumonia pneumococcal) was considered as medically significant.
Sex: F
Vaccine: PNC13, PPV
Symptoms: Pneumonia pneumococcal, Streptococcus test positive
Clinical narrative: Pneumonia caused by Streptococcus pneumoniae; Information has been download from Regulatory Authority on 12-JAN-2024.  This spontaneous report was referring to an elderly female patient (65-69 years old). The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided). The patient received pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) for 1 time in total. On an unknown date, the patient was vaccinated with pneumococcal vaccine conj 13v (crm197) (PREVENAR 13) for prophylaxis (strength, dose, formulation, lot #, expiry date, and route of administration were not provided). The patient received pneumococcal vaccine conj 13v (crm197) (PREVENAR 13) for 1 time in total.  On an unknown date in 2022, the patient experienced pneumonia caused by streptococcus pneumoniae (Streptococcus pneumoniae pneumonia), the streptococcus pneumoniae serotyping was not available. At the time of reporting, the outcome of the event streptococcus pneumoniae pneumonia was unknown.   The causal relationship between streptococcus pneumoniae pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Bacteraemia, Bacterial test positive
Clinical narrative: Bacteraemia; Information has been received from regulatory authority on 12-JAN-2024.  This spontaneous report has been downloaded from regulatory authority and refers to an adult (between 35 and 39 years old; reported as age group 35-39) female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (exact dose, strength, lot #, expiry date, and route of administration were not provided). It was reported that the patient received total of 1 vaccination.  In 2015, the patient experienced bacteraemia, serotype: not available. The outcome of the event was not provided.  The causal relationship between bacteraemia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not reported.  Upon internal review, the event of bacteraemia has been determined to be medically significant.
Sex: M
Vaccine: PNC, PPV
Symptoms: Pneumococcal infection
Clinical narrative: Pneumococcal infection; Information has been received from health authority via Case Line Listing on 12-JAN-2024 concerning an adult male patient (reported as 20-24 years old). The patient's concurrent condition, medical history and concomitant medication were not provided.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis. On unknown dates, the patient was vaccinated with 2 doses of pneumococcal vaccine conj 7v (crm197) (PREVENAR) (formulation, strength, indication, dose, route of administration, lot#, and expiration date were not reported).  On an unknown date in 2022, the patient experienced pneumococcal infection, streptococcus pneumoniae serotyping reported as not available. The outcome of the event was unknown.  The causal relationship between the event and the vaccines was not provided.  Upon internal review, the event of Pneumococcal infection was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal infection, Streptococcus test
Clinical narrative: Pneumococcal infection; Information has been received from Surveillance System via Case Line Listing on 12-JAN-2024 concerning an elderly male patient (reported as 85+ years old). The patient's concurrent condition, medical history and concomitant medication were not provided.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.   On an unknown date in 2016,  the patient experienced pneumococcal infection, streptococcus pneumoniae serotyping result reported as not available. The outcome of the event was unknown.  The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of Pneumococcal infection was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia, Streptococcus test
Clinical narrative: Pneumonia; Information has been received from regulatory authority via Case Line Listing on 12-JAN-2024 concerning an adult female patient (reported as 55-59 years old). The patient's concurrent condition, medical history and concomitant medication were not provided.  On an unknown date, the patient was vaccinated with the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.   On an unknown date in 2016, the patient experienced pneumonia, streptococcus pneumoniae serotyping showed not available. The outcome of the event was unknown.  The causal relationship between the event and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of pneumonia pneumococcal was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information has been received from Health Authority on 12-JAN-2024.  This spontaneous report was referring to a female adult patient (age: 60-64). The patient's medical history, historical drugs, concurrent conditions, and concomitant drugs were not reported  On an unknown date, the patient was vaccinated with the second dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.  On an unknown date in 2012, the patient experienced Streptococcus pneumoniae pneumonia. On an unknown date in 2012, Streptococcus pneumoniae serotyping was not available . At the time of reporting, the outcome of the event Streptococcus pneumoniae pneumonia was not known.  The causal relationship between the event and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) was not provided.  Upon internal review, the event of streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal, Streptococcus test
Clinical narrative: Streptococcus pneumoniae pneumonia; Information has been downloaded from database on 12-JAN-2024.  This spontaneous report was referring to a male elderly patient (age: 80-84). The patient's medical history, historical drugs, concurrent conditions, and concomitant drugs were not reported.   On an unknown date, the patient was vaccinated with the first dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.   On an unknown date in 2009, the patient experienced streptococcus pneumoniae pneumonia. On an unknown date in 2009, the patient's streptococcus pneumoniae serotyping result was not available. The outcome of the event was unknown. The causal relationship between the event and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) was not provided.  Upon internal review, the event of pneumonia pneumococcal was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumonia pneumococcal, Streptococcus test
Clinical narrative: Streptococcus pneumoniae pneumonia; Information has been received from regulatory authority (Agency# not provided) via company employee on 12-JAN-2024.  This spontaneous report concerned an elderly female patient with age 70-74 years old. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with the 1st dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2016, the patient experienced Streptococcus pneumoniae pneumonia. On an unknown date in 2016, Streptococcus pneumoniae serotyping not available. At the time of reporting, the outcome of the event was not known. The causal relationship between event and suspect vaccine was not provided.  Upon internal review, the event Streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Meningitis pneumococcal, Pneumococcal infection
Clinical narrative: Meningitis; Information was received by database via Case Line Listing and from a company representative on 12-JAN-2024 concerning an adult (reported as 35-39 years old) female patient. The patient's concurrent condition, medical history and concomitant medication were not provided.  On an unknown date, the patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (reported as 23vPPV, vaccine not available for serotype, total vaccinations: 1) (strength, dose, lot #, expiry date, route of administration, and anatomical location were not provided) as prophylaxis.  On an unknown date in 2016, the patient experienced invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae, clinically category reported as meningitis (Streptococcus pneumoniae serotyping: not available) (meningitis pneumococcal). At the time of reporting, the outcome of the event was not reported.   The causal relationship between meningitis pneumococcal and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of meningitis pneumococcal was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal, Streptococcus test positive
Clinical narrative: Streptococcus pneumoniae pneumonia; Information has been received from Regulatory Agency on 12-JAN-2024.  This spontaneous report has been downloaded from Surveillance System and referring to an elderly male patient (age: 70-74 years old). The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided). Total 1 dose was vaccinated.  On an unknown date in 2016, the patient experienced Streptococcus pneumoniae pneumonia, streptococcus pneumoniae serotyping showed Not Available. At the time of reporting, the outcome of the event was unknown. The causal relationship between Streptococcus pneumoniae pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event of Streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Meningitis pneumococcal, Pneumonia pneumococcal, Septic arthritis streptococcal
Clinical narrative: Streptococcus pneumoniae meningitis; Streptococcus pneumoniae pneumonia; Information has been received from Regulatory agency (Surveillance System) (Agency# not provided) via company employee on 12-JAN-2024.  This spontaneous report concerned an elderly male patient with age more than 85 years old. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with the 1st dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2016, the patient experienced Streptococcus pneumoniae meningitis and Streptococcus pneumoniae pneumonia. On an unknown date in 2016, Streptococcus pneumoniae serotyping was not available. It was also reported that vaccine was not available for serotype. At the time of reporting, the outcome of the events was not known. The causal relationship between events and suspect vaccine was not provided.  Upon internal review, the event Pneumococcal infection and Septic arthritis streptococcal were determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal, Streptococcus test
Clinical narrative: Streptococcus pneumoniae pneumonia; Information has been received from Agency 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Authority and referring to a male adult patient (age: 55-59 years old). The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On an unknown date, the patient was vaccinated 4 times of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, administered for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2016, the patient experienced streptococcus pneumoniae pneumonia. On an unknown date in 2016, streptococcus pneumoniae serotyping showed not available. At the time of reporting, the outcome of the event streptococcus pneumoniae pneumonia was not known.  The causal relationship between event streptococcus pneumoniae pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event of streptococcus pneumoniae pneumonia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumococcal bacteraemia, Streptococcus test
Clinical narrative: Pneumococcal bacteraemia; Information has been received from health authority (Agency# not provided) via company employee on 12-JAN-2024.  This spontaneous report concerned an adult female patient with age 55-59 years old. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with the 1st dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2016, the patient experienced Pneumococcal bacteraemia. On an unknown date in 2016, Streptococcus pneumoniae serotyping was not available. Serotype was reported as unknown. At the time of reporting, the outcome of the event was not known. The causal relationship between event and suspect vaccine was not provided.  Upon internal review, the event Pneumococcal bacteraemia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumococcal bacteraemia, Streptococcus test
Clinical narrative: Bacteremia; Information has been received from Agency on 12-JAN-2024.  This spontaneous report has been downloaded from National Notifiable Diseases Surveillance System (NNDSS) and referring to an adult male patient (age: 50-54 years old). The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On unknown dates, the patient was vaccinated with one dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, 1 time, for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2009, the patient experienced bacteremia (pneumococcal bacteraemia). Streptococcus pneumoniae serotyping showed not applicable. At the time of reporting, the outcome of the event pneumococcal bacteraemia was not known.  The causal relationship between pneumococcal bacteraemia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event of pneumococcal bacteraemia was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumococcal bacteraemia
Clinical narrative: Bacteraemia; Information has been received from Agency on 12-JAN-2024.  This spontaneous report has been downloaded from National Notifiable Diseases Surveillance System (NNDSS) referring to an adult female patient (age: 45-49 years old). The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On unknown date, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, 1 time, as prophylaxis (strength, dose, lot#, expiry date, route of administration and anatomical location not reported).  On an unknown date in 2009, the patient experienced pneumococcal bacteraemia. On an unknown date in 2009, streptococcus pneumoniae serotyping showed not available. At the time of reporting, the outcome of the event pneumococcal bacteraemia was unknown. The action taken with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not applicable.  The causal relationship between pneumococcal bacteraemia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event of pneumococcal bacteraemia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal, Streptococcus test positive
Clinical narrative: Streptococcus pneumoniae pneumonia; Information has been downloaded from National Notifiable Diseases Surveillance System (NNDSS) on 12-JAN-2024.  This spontaneous report was referring to a male adult patient (age: 25-29). The patient's medical history, historical drugs, concurrent conditions, and concomitant drugs were not reported.   On an unknown date, the patient was vaccinated with the first dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) injection (strength, dose, route of administration, lot#, and expiration date were not reported) for prophylaxis.   On an unknown date in 2009, the patient experienced streptococcus pneumoniae pneumonia. On an unknown date in 2009, the patient's streptococcus pneumoniae serotyping result was not available. The outcome of the event was unknown. The causal relationship between the event and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23) was not provided.  Upon internal review, the event of pneumonia pneumococcal was determined to be medically significant.
Sex: F
Vaccine: PPV
Symptoms: Pneumococcal infection
Clinical narrative: Pneumococcal infection; Information has been received from Agency on 12-JAN-2024 and referred to a female patient (age group: 40-44). The patient's medical history, concurrent condition, and concomitant therapy were not reported.   On an unknown date, the patient received the first dose of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).   On an unknown date in 2022, the patient experienced pneumococcal infection. On an unknown date in 2022, streptococcus pneumoniae serotyping showed not available. At the time of reporting, the outcome of the event was not provided. The action taken with vaccine regarding event was not applicable.   The causal relationship between event and vaccine was not provided.  Upon internal review, the event of pneumococcal infection was determined to be medical significant event.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia, Streptococcus test positive
Clinical narrative: Pneumonia; Information has been received from Agency on 12-JAN-2024.  This spontaneous report has been downloaded from Regulatory Authority and referring to a male patient (age: 75-79 years old). The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection, 1 time, administered for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided).  On an unknown date in 2009, the patient experienced pneumonia. On an unknown date in 2009, Streptococcus pneumoniae serotyping showed not available. At the time of reporting, the outcome of the event pneumonia was not known. The action taken with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) regarding pneumonia was reported as not applicable.    The causal relationship between pneumonia and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was unknown.  Upon internal review, the event of pneumonia was determined to be medically significant.
Sex: M
Vaccine: PPV
Symptoms: Pneumonia pneumococcal
Clinical narrative: Pneumonia; Information was received by The Regulatory Authority and from a company representative on 12-JAN-2024 concerning an adult (reported as 40-44 years old) male patient. The patient's concurrent condition, medical history and concomitant medication were not provided.  On unknown dates, the patient was vaccinated with two doses of pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection (reported as 23vPPV, vaccine not available for serotype, total vaccinations: 2) (strength, dose, lot #, expiry date, route of administration, and anatomical location were not provided) as prophylaxis.  On an unknown date in 2016, the patient experienced invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae, clinically category reported as pneumonia (Streptococcus pneumoniae serotyping: not available) (pneumonia pneumococcal). At the time of reporting, the outcome of the event was not reported.   The causal relationship between pneumonia pneumococcal and pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) was not provided.  Upon internal review, the event of pneumonia pneumococcal was determined to be medically significant.